0.09
-5.57%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neovacs
Its shares trade on Euronext Paris under the ticker ALNEV.PA. It has been listed since 15 April 2010. In the fiscal year to 31 December 2025, it reported revenue of €161,780 and a net loss of €4.9m. At that date it held total assets of €22.1m and shareholders' equity of €18.0m.
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory, and cancerous diseases. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Apr 2010
- Employees
- 24
- Website
- neovacs.fr ↗
Leadership
Pay as last reported
- Mr. Hugo BrugiereChairman of the Board, Chief Executive Officer, since 2020€85,000
- Mr. Vincent SerraChief Operating Officer, Chief Scientific Officer€188,798
- Mr. Bernard FangetVice President - Pharmaceutical Affairs
- Dr. Olivier DhellinDirector of Pharmaceutical Development
- Mr. Jean-Jacques BertrandDirector, since 2003€6,000
- Mme. Muriel HaimDirector
- Monsieur Baudouin HalloDirector€9,000
- Mr. Daniel ZaguryDirector€6,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Neovacs SA develops Kinoids for autoimmune and inflammatory diseases with 24 employees.
- Neovacs SA focuses on TNF-Kinoids, IFN-Kinoids, and VEGF-Kinoids for treatment.
- Neovacs SA operates in France and the United States with a joint venture in 2016.
Weaknesses
- Neovacs SA has only 24 employees for biotechnology development.
- Neovacs SA's IPO was in 2010 with limited market presence.
- Neovacs SA's focus on Crohn's disease and lupus limits broader applications.
Opportunities
- Neovacs SA can expand Kinoids for cancerous diseases beyond autoimmune conditions.
- Neovacs SA's joint venture with Stellar Biotechnologies Inc offers new market access.
- Neovacs SA's research in immunotherapy could attract additional partnerships.
Threats
- Neovacs SA faces competition from established biotechnology firms in France.
- Neovacs SA's small size may hinder funding for large-scale trials.
- Neovacs SA's reliance on Kinoids for specific diseases poses market risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.